July 7, 2023 Non Regulatory Interview with LIDDS’s Chairman of the Board published on the company’s website
July 6, 2023 Regulatory LIDDS announces closure of R&D project with Johnson & Johnson Enterprise Innovation Inc.
June 27, 2023 Regulatory LIDDS announces Cost Containment Measures to maximise the runway to reach a License Agreement
May 2, 2023 Non Regulatory LIDDS participates in LSX World Congress and ERLIG Therapeutic Oligo meetings
March 14, 2023 Non Regulatory LIDDS participates in BIO-Europe Spring and EACR Immuno-Oncology Meetings
February 20, 2023 Regulatory LIDDS’ rights issue is registered and trading in Paid Subscribed Shares ceases
February 7, 2023 Regulatory Correction of pressrelease: LIDDS announces preliminary outcome in the Rights Issue
January 23, 2023 Non Regulatory The subscription period in LIDDS’ rights issue is starting today and the CEO has participated in an interview with Erik Penser Bank
January 9, 2023 Regulatory Bulletin from the Extraordinary General Meeting in LIDDS AB (publ) on the 9 January 2023
January 9, 2023 Non Regulatory LIDDS signs a deal with Alira Health on sell-side support in Licensing